Mechanism of Action: How MaculaPM® Works

The science behind MaculaPM® centers on a novel pathway. L-DOPA derived from Mucuna pruriens activates GPR143 receptors on retinal pigment epithelial (RPE) cells — triggering a cascade that restores protective balance in the macula. This mechanism was identified through epidemiological observations that Parkinson's patients taking L-DOPA showed dramatically lower AMD prevalence — a finding that sparked the University of Arizona research program underlying MaculaPM®.

A Closer Look at Retinal Biology


Natural L-DOPA from Velvet Bean (Mucuna pruriens) serves as a potent regulator of eye health by signaling the GPR143 receptor in the RPE.
L-DOPA production in our eyes slows down as we age, particularly after age 60. When L-DOPA levels drop, the signaling pathways that maintain retinal health and regulate blood vessel formation become compromised. MaculaPM® incorporates this key ingredient to support retinal signaling and macular health.*

The 5-Step Mechanism of Action

L-DOPA Absorption

Natural L-DOPA from Mucuna pruriens crosses into systemic circulation and reaches retinal tissue during overnight absorption, where it serves as a potent regulator of eye health by signaling the GPR143 receptor.

GPR143 Receptor Activation

In the eye, L-DOPA from Mucuna pruriens serves as a potent regulator of eye health by signaling the GPR143 receptor in the RPE — a receptor uniquely concentrated in the macula.

VEGF Downregulation

GPR143 activation helps modulate vascular endothelial growth factor (VEGF), supporting the normal regulation of blood vessel development in the retina.*

PEDF Upregulation

Simultaneously, pigment epithelium-derived factor (PEDF) is increased. PEDF is a naturally occurring protein secreted by the RPE that provides potent neuroprotective and anti-angiogenic support to photoreceptors.

Overnight Repair Support

L-DOPA from Mucuna pruriens serves as a potent regulator of eye health by signaling the GPR143 receptor, peaking during the dark phase. Melatonin's nocturnal antioxidant peak, combined with lutein and zeaxanthin's photoprotection, reinforces macular resilience during this critical sleep-phase cellular repair. MaculaPM® is formulated to provide nutritional support for these retinal pathways during overnight cellular maintenance.*

MaculaPM®: Developed by Eye Health Researchers. Formulated to Support Lifelong Macular Health.

About MaculaPM®

MaculaPM® was developed by a research team with deep roots in eye health science, including investigators whose work has received support from the NIH and the BrightFocus Foundation, in collaboration with researchers from the University of Arizona and the Marshfield Clinic. The team includes Dr. Robert Snyder, MD, former Chair of the Department of Ophthalmology, along with Dr. Brian McKay and Dr. Murray Brilliant of the University of Arizona.

MaculaPM® is formulated with a targeted combination of dietary supplement ingredients studied for their roles in supporting retinal health. These include natural L-DOPA derived from Mucuna pruriens (velvet bean), melatonin, and key nutrients from the AREDS2® formula, all selected based on published scientific literature examining their functions in the eye.

The Science Behind the Formulation

Over a 15-year period, the researchers behind MaculaPM® conducted extensive work exploring how naturally occurring compounds in the eye change over time and what that may mean for long-term macular health. Their investigative work, drawing on analysis of large patient populations including data from tens of millions of medical records, identified a relationship between L-DOPA signaling in the retina and the mechanisms the eye uses to maintain healthy tissue and regulate blood vessel formation.

Published research registered with the NIH and appearing in peer-reviewed journals has examined L-DOPA's role as a signaling molecule in the retina, including its relationship to Vascular Endothelial Growth Factor (VEGF) and Pigment Epithelium-Derived Factor (PEDF), two proteins involved in the eye's natural regulatory processes. Notably, natural L-DOPA production in the retina tends to decline in individuals over 60, as does melatonin secretion.

Melatonin plays a role in regulating the body's circadian rhythm, which scientific literature suggests is important for supporting normal retinal function. L-DOPA signaling in the retina operates in part under circadian control, with activity typically peaking in the evening hours.

MaculaPM® combines these two naturally occurring compounds with the evidence-based AREDS2® nutrient profile to support comprehensive macular health in older adults.

A Closer Look at Retinal Biology

The retina depends on a critical support layer called the Retinal Pigment Epithelium (RPE). RPE cells produce melanin pigment, and a byproduct of that synthesis process is L-DOPA. As we age, melanin synthesis in the RPE slows, reducing natural L-DOPA production. This reduction appears to be more pronounced in lightly pigmented individuals and typically accelerates after age 60.

In the eye, L-DOPA functions as a signaling molecule that interacts with GPR143, a G-protein coupled receptor. Research indicates that this signaling relationship influences the regulation of VEGF and supports the activity of PEDF, a protein naturally secreted by the RPE that scientific literature associates with neuroprotective activity, photoreceptor support, and healthy management of blood vessel growth.

Melatonin contributes to the circadian regulation of these processes. Because both L-DOPA and melatonin production decline naturally with age, MaculaPM® is designed to provide dietary support for these pathways during a period when the eye's own production may be diminished.

MaculaPM® Nighttime Eye Support

$57.99

Science-based · Doctor-derived · University-researched
MaculaPM® — Nighttime eye support formulated around retinal signaling and circadian biology.

While you sleep, the eye performs its most important maintenance and renewal processes. MaculaPM® is a once-nightly formula built around this biology — combining L-DOPA, melatonin, and key macular nutrients selected for their roles in retinal signaling, nighttime circadian function, and macular support.†

Developed by researchers at the University of Arizona. Backed by US patents 11,969,401 and 9,173,862. 60 capsules — 30-day supply.

What's inside — 6 evidence-based ingredients

L-DOPA (from Mucuna pruriens seed extract) — 100 mg
Supports retinal signaling through the GPR143 receptor in the retinal pigment epithelium. Involved in both pigment biology and retinal maintenance.

Melatonin — 5 mg
A naturally occurring hormone that regulates circadian rhythm, aligning the formula with the eye's overnight maintenance and renewal cycle.

Lutein (from Tagetes erecta L. flower) — 5 mg
Concentrates in the macula to help filter high-energy blue light and support macular pigment optical density. Included at doses studied in AREDS2 clinical trials.†

Zeaxanthin (from Tagetes erecta L. flower) — 2 mg
Works alongside lutein in the fovea to support central vision and macular pigment. Also studied in AREDS2 clinical trials.†

Vitamin C (as Ascorbic Acid) — 100 mg
An antioxidant that helps support the body's natural defenses against oxidative stress in retinal cells. Included in the AREDS clinical formula.

Vitamin E (as D-Alpha Tocopheryl Acid Succinate) — 35 mg
Supports antioxidant defense in photoreceptor cell membranes and retinal tissue. Part of the AREDS and AREDS2 clinical trial evidence base.

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.